Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced financial results for the second quarter ended June 30, 2021 and reviewed recent corporate updates.
- This transaction is a validation of our mRNA platform and a testament to the talented Translate Bio team.
- Translate Bio ended the second quarter of 2021 with $667.2 million in cash, cash equivalents and investments and 75,343,712 shares of common stock outstanding.
- General and administrative expenses of $11.9 million during the second quarter of 2021, compared to $8.6 million for the same period in 2020.
- Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.